Repatha® at ESC Congress 2020
ESC Congress 2020 – The Digital Experience pushed new boundaries by bringing together an even larger cardiology
community for an exclusively online programme of groundbreaking science.
Important new data were discussed during the Congress, including the suboptimal control of LDL-C in cardiovascular
patients across Europe, the value of lipid-lowering therapy combinations such as PCSK9 inhibitors added to optimised
statins to improve LDL-C goal attainment, and real-world experience with Repatha® (evolocumab) in routine clinical
Key studies presented at ESC 2020:
DA VINCI Study1
- An EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care.
- The study highlights the gap between ESC/EAS Guideline-recommended LDL-C goals3 and clinical practice across a
broad range of patients.1
- A multicentre, observational cohort study conducted in 10 European countries involving patients with hyperlipidaemia
- Repatha® use in routine clinical practice is aligned with 2016 clinical guidelines4 and has very high rates of patient
compliance and persistence†5 which should offer significant benefits in these very-high-risk patients with ASCVD.